GLOW Blend is a three-peptide research formulation containing:

GHK-Cu – 50 mg
BPC-157 – 10 mg
TB-500 (Full Sequence Thymosin β4) – 10 mg

Rather than representing a new peptide, GLOW combines three established regenerative research compounds into a single formulation. Each component has an extensive independent research profile covering different aspects of tissue biology, allowing investigators to explore multiple regenerative pathways within one experimental blend.

Why GLOW matters in regenerative research

Tissue repair involves a complex interaction between extracellular matrix remodelling, cell migration, angiogenesis and connective tissue organisation. For this reason, regenerative research often examines multiple biological pathways rather than a single signalling mechanism.

GLOW combines three of the most widely recognised peptides in regenerative research:

GHK-Cu – extracellular matrix regulation, collagen biology and connective tissue physiology.
BPC-157 – tendon, ligament, muscle and gastrointestinal research.
TB-500 – Thymosin β4 biology, cell migration and tissue remodelling.

Each peptide has a distinct research profile, making GLOW a practical formulation for laboratories interested in complementary regenerative mechanisms rather than a single molecular target.

The three components of GLOW

GHK-Cu (50 mg)

An endogenous copper-binding tripeptide extensively investigated in extracellular matrix biology, collagen regulation, skin physiology and connective tissue remodelling.

BPC-157 (10 mg)

A stable gastric pentadecapeptide widely studied in tendon, ligament, muscle, angiogenesis and gastrointestinal research.

TB-500 (10 mg)

A full-sequence Thymosin β4 peptide investigated in cell migration, actin dynamics, angiogenesis and tissue repair.

Together these three peptides represent complementary areas of regenerative biology while retaining their own independent research backgrounds.

Why GLOW is widely investigated in tissue repair research

The individual components of GLOW have each been investigated in published research involving:

tendon and ligament biology
connective tissue repair
skeletal muscle research
wound healing
angiogenesis
extracellular matrix remodelling
skin physiology
musculoskeletal research

Because these research areas frequently overlap, combining GHK-Cu, BPC-157 and TB-500 into a single formulation has become increasingly common in laboratory research workflows. However, published evidence relates primarily to the individual peptide components, and should not be interpreted as demonstrating equivalent findings for the combined blend.

How GLOW differs from KLOW

Although both formulations are built around the same regenerative foundation, they have different research emphasis.

GLOW Blend

GHK-Cu – 50 mg
BPC-157 – 10 mg
TB-500 – 10 mg

Primary focus:

connective tissue biology
extracellular matrix remodelling
musculoskeletal research
regenerative signalling

KLOW Blend

Contains the same three peptides plus KPV (10 mg).

The addition of KPV extends the research scope to include inflammatory and immune-related pathways, making KLOW a broader formulation for laboratories investigating both regenerative and inflammation-related biology.

Human and preclinical research

There are currently no dedicated clinical studies evaluating GLOW as a three-peptide formulation.

Instead, the scientific rationale for GLOW is based on the extensive published literature describing each of its individual components:

GHK-Cu in connective tissue and extracellular matrix biology.
BPC-157 in gastrointestinal and musculoskeletal research.
Thymosin β4/TB-500 in cell migration and tissue remodelling.

Researchers should therefore interpret findings according to the evidence available for each peptide rather than assuming additive or synergistic effects for the blend itself.

Published safety considerations

Published safety information for GLOW is derived from the available literature on its individual peptide components rather than from studies of the combined formulation.

Accordingly, observations reported for GHK-Cu, BPC-157 or TB-500 should be considered independently, while recognising that the complete blend has not been evaluated in dedicated clinical trials.

Product characteristics

Application: laboratory and analytical research
Use restriction: not for human consumption; not for medical, veterinary or cosmetic use
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (you can find Certificate of Analysis under product pictures).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.
Purity: ≥ 98% (HPLC)
Appearance: light blue lyophilized powder (due to GHK-Cu content)
Composition: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg Tb4 per vial
Molecular formula (GHK-Cu): C₁₄H₂₂CuN₆O₄
Molecular formula (BPC-157): C₆₂H₉₈N₁₆O₂₂
Molecular formula Thymosin Beta-4 (full sequence): C₂₁₄H₃₅₃O₇₉N₅₇S₁
Storage: unopened lyophilized vials are best stored refrigerated at 2–8°C, which is the storage method confirmed by our manufacturing partner and suitable for up to 24 months. Refrigeration is preferred because it minimizes unnecessary freeze–thaw cycles during routine handling. If substantially longer-term storage is required, unopened lyophilized vials may also be kept frozen. Once reconstituted, always store at 2–8°C and do not freeze.

Reconstitution and handling

KLOW is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with bacteriostatic water before use. To help preserve structural integrity, add the chosen solvent slowly against the inside wall of the vial rather than directly onto the peptide cake, and avoid vigorous shaking. Gentle swirling is generally sufficient once the peptide has fully dissolved. Standard laboratory practice also includes allowing refrigerated vials to reach room temperature before reconstitution to minimise condensation inside the vial.

For other solvent selection, concentration planning and storage guidance, see the full Peptide Reconstitution Guide and Reconstitution Calculator.

Key published studies

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018.

A comprehensive review describing GHK-Cu’s role in extracellular matrix biology, collagen regulation and regenerative signalling.

Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design, 2011.

The foundational review summarising BPC-157 research across gastrointestinal, angiogenesis and regenerative biology.

Goldstein AL, Kleinman HK. Thymosin β4: Structure, Function and Biological Properties Supporting Current and Future Clinical Applications. Annals of the New York Academy of Sciences, 2010.

The landmark review covering Thymosin β4 biology, cell migration, angiogenesis and tissue remodelling.

Frequently Asked Questions

What is GLOW Blend?

GLOW Blend is a research formulation combining GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg) in a single lyophilised vial. Each peptide has been independently investigated in published research for different aspects of regenerative biology, including connective tissue remodelling, angiogenesis and musculoskeletal research.

Which peptides are included in GLOW?

Each vial contains:

GHK-Cu – 50 mg
BPC-157 – 10 mg
TB-500 (Full Sequence Thymosin β4) – 10 mg

Together these peptides represent complementary areas of regenerative research, ranging from extracellular matrix biology and connective tissue physiology to cell migration and soft-tissue repair.

Why are GHK-Cu, BPC-157 and TB-500 combined?

Each peptide has a different research focus. GHK-Cu is widely investigated in collagen biology and connective tissue remodelling, BPC-157 in tendon, ligament and gastrointestinal research, and TB-500 in cell migration and tissue remodelling. Combining them allows researchers to investigate multiple regenerative pathways within a single experimental formulation. Current published evidence relates to the individual peptides, not to the blend itself.

What research areas commonly investigate GLOW Blend?

Based on the published literature for its individual components, GLOW is relevant to research involving tissue repair, tendon and ligament biology, connective tissue remodelling, angiogenesis, musculoskeletal research, wound healing and extracellular matrix regulation.

How does GLOW differ from KLOW?

GLOW combines GHK-Cu, BPC-157 and TB-500. KLOW contains the same three peptides but also includes KPV, extending the research scope to inflammatory and immune-related pathways. GLOW is therefore focused primarily on regenerative biology, while KLOW adds an additional inflammation-focused component.

Can research on the individual peptides be applied directly to GLOW Blend?

Not necessarily. GHK-Cu, BPC-157 and TB-500 each have substantial independent research literature, but there are currently no large published clinical studies evaluating the combined GLOW formulation. The scientific rationale for the blend is based on the complementary biology of its individual components rather than direct evidence for the blend itself.

Is this product intended for human use?

No. GLOW Blend supplied by LIFE Peptide is provided strictly for laboratory and analytical research. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published studies summarises the scientific literature relating to the individual peptide components rather than the intended use of the combined formulation.

Related research context

GLOW belongs to the Healing & recovery peptide research category, combining compounds frequently studied for complementary regenerative signaling pathways.
Researchers exploring multi-pathway recovery models may also examine:

BPC-157 — tissue signaling and angiogenesis research
Thymosin β4 (TB-500) — migration and cytoskeletal signaling
GHK-Cu — copper peptide and extracellular remodeling pathways
Wolverine (BPC-157 + TB-500) — dual-pathway recovery blend

Looking for additional investigation of inflammation-related pathways? See KLOW Blend.

For broader context, see the Healing & recovery research guide.

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.

Multi-pathway blend

směs GLOW / BPC-157 + Tb4 (TB-500) + GHK-Cu